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Abstract
A common problem in the assessment of Ki67 proliferative index in well-differentiated 
gastrointestinal neuroendocrine tumors is distinguishing tumor from non-tumor. This is because 
background stromal lymphocytes, entrapped non-neoplastic glands, and the delicate vascular 
network characteristic of neuroendocrine tumors frequently contain a subset of proliferating cells. 
Furthermore, in small biopsies, crush and cautery artifact can alter the morphologic appearance of 
tumor cells, making the Ki67 proliferative index more difficult to assess. To address these issues, 
we developed a synaptophysin-Ki67 double stain using a commercially available 
immunohistochemistry kit, allowing simultaneous visualization of tumor and proliferating nuclei. 
To test this method, 3 gastrointestinal pathologists individually graded 50 gastrointestinal 
neuroendocrine tumors first using synaptophysin-Ki67 double-stained slides and then, after a 
wash-out period, using Ki67-only stained slides (along with routine hematoxylin and eosin-stained 
slides). Interobserver agreement on Ki67 proliferative index was moderate using the Ki67-only 
stained slides (intraclass correlation 0.51, 95% confidence interval 0.35-0.66) and improved using 
the synaptophysin-Ki67 double stain (intraclass correlation 0.79, 95% confidence interval 
0.69-0.86). Similarly, interobserver agreement on tumor grade was fair with Ki67-only stained 
slides (kappa = 0.39, P<0.001) and improved with the double stain (kappa = 0.58, P<0.001). 
Analysis of individual pathologists' scores revealed that fewer total number of tumor cells counted 
correlated with higher grade designation and appeared to contribute to grade discordance. In 
tumors cited as particularly challenging to assess by pathologists, 3 of 4 tumors were grade 
discordant with the Ki67-only stain, whereas all 4 tumors were grade concordant with the 
synaptophysin-Ki67 stain. The synaptophysin-Ki67 double stain is the first technique to 
specifically address the histomorphologic challenges of evaluating Ki67 proliferative index in 
well-differentiated gastrointestinal neuroendocrine tumors. Although further validation is needed, 
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this study provides evidence that the synaptophysin-Ki67 double stain can improve interobserver 
agreement.
Keywords
Neuroendocrine tumor; carcinoid; Ki-67; Ki67; synaptophysin
Introduction
The current edition of the World Health Organization Classification of Tumours of the 
Digestive System published in 2010 proposes a unified classification for neuroendocrine 
neoplasms of all gastrointestinal sites. (1) In this system, tumor grade is entirely dependent 
on proliferative rate, as determined by mitotic count and/or Ki67 proliferative index. More 
recently, it has become clear that tumor grade based on Ki67 proliferative index is a better 
measure of tumor behavior than mitotic count. (2-4) Thus, accurate assessment of Ki67 
proliferative index is essential for determination of tumor grade. This information, in turn, is 
essential for accurate prognostication and optimal patient management.
A common problem in the assessment of Ki67 proliferative index in well-differentiated 
neuroendocrine tumors is that background stromal lymphocytes and entrapped non-
neoplastic glands frequently contain proliferating cells. The delicate vascular network 
characteristic of neuroendocrine tumors also contains a subset of proliferating cells. These 
non-neoplastic cells can be difficult to distinguish from tumor cells on the Ki67 stain and, if 
mistakenly counted, can artificially elevate the proliferative index. Furthermore, in small 
biopsies, crush and cautery artifact can alter the morphologic appearance of tumor cells, 
making the Ki67 proliferative index more challenging to assess.
Because the threshold between grade 1 and grade 2 gastrointestinal neuroendocrine tumors 
is quite low (by 2010 World Health Organization definition, grade 1 tumors have a Ki67 
index of less than or equal to 2%, whereas grade 2 tumors have a Ki67 index of 3 to 20%), 
(1) mistaking even 1 or 2 non-tumor Ki67-positive cells as neoplastic or missing 1 or 2 
Ki67-positive tumor cells could mean the difference between a grade 1 and grade 2 
designation. Making matters more complex, the guidelines do not specify how to interpret 
Ki67 proliferative indices falling between 2 and 3%, which has led to a variety of 
interpretations (or no explanation of methodology at all) in the literature. (2, 5-11) More 
recently, the North American Neuroendocrine Tumor Society and others have recommended 
that grade 1 tumors be designated as those with Ki67 proliferative index of <3%. (12-15). At 
this time, the general consensus is to use the <3% cut-off for grade 1 tumors, and this 
clarification will also be reflected in the forthcoming edition of the World Health 
Organization Classification of Tumours of the Digestive System (per Dr. Ralph Hruban, 
personal communication). However, given that the majority of well-differentiated 
gastrointestinal neuroendocrine tumors have a Ki67 proliferative index in the 0-5% range, 
this improvement does not obviate the need for accurate and precise assignment of Ki67 
proliferative index to discriminate between grade 1 and grade 2 tumors.
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Synaptophysin is a glycoprotein widely expressed in normal neuroendocrine cells of the 
gastrointestinal tract as well as GI neuroendocrine neoplasms. We hypothesized that 
simultaneous visualization of tumor by synaptophysin expression and proliferating nuclei by 
Ki67 expression would facilitate more consistent interpretation of gastrointestinal 
neuroendocrine tumor proliferative index and tumor grade by aiding in the distinction of 
tumor from non-tumor. To test this idea, we developed a synaptophysin-Ki67 double stain 
using a commercially available immunohistochemistry kit and conducted a 2-part 
interobserver study, first using synaptophysin-Ki67 double-stained slides and then, after a 
wash-out period, using Ki67-only stained slides (along with routine hematoxylin and eosin-
stained slides). The primary goal of the study was to assess interobserver agreement in 
regard to Ki67 proliferative index and tumor grade. The secondary goal was to evaluate the 
impact of individual observer, specimen type (i.e., biopsy versus resection), and staining 
method (i.e., double stain versus Ki67-only stain) on proliferative index as compared to a 
gold standard assessment in order to identify possible sources of bias.
Materials and Methods
Cases
This study was approved by the Institutional Review Board at the University of California 
Davis Medical Center. Well-differentiated gastrointestinal neuroendocrine tumors (stomach, 
small bowel, appendix, colon, rectum, and pancreas) diagnosed at the University of 
California Davis Medical Center from January 1, 2008 to August 1, 2014 were identified 
through a search of the pathology database. Of the 95 eligible cases, 53 of the most recent 
cases were selected based on availability of slides and paraffin blocks. Three of these cases 
were utilized for optimization of the immunohistochemical staining protocol: 1 randomly 
selected tumor from year 2009, 1 randomly selected tumor from year 2011, and 1 randomly 
selected tumor from year 2013 (allowing evaluation of staining quality on tissue blocks 
stored for different lengths of time). The 50 cases used in the Ki67 quantitative analysis 
derived from various GI sites (8 stomach, 13 small bowel, 5 appendix, 3 colon, 16 rectum, 5 
pancreas) and represented both biopsies (n=29) and resections (n=21).
Immunohistochemistry
The synaptophysin-Ki67 double immunostain was prepared using the DAKO Envision Flex, 
High pH mini kit (DAKO, Carpinteria, CA) with the G2 system alkaline phosphatase rabbit/
mouse Permanent Red kit and DAKO antibodies: synaptophysin (clone DAK-SYNAP, 
IR660 FLEX RTU SYNAPTOPHYSIN) and Ki-67 (clone MIB-1, IR626 FLEX RTU 
KI-67). This kit is designed for simultaneous detection of two antigens using horseradish 
peroxidase with DAB as one chromogen and alkaline phosphatase with Permanent Red as 
the second chromogen. The DAB chromogen was chosen for detection of Ki67, and the 
Permanent Red chromogen was chosen for detection of synaptophysin. The initial double 
stain protocol was designed by the local DAKO representative and was deemed adequate by 
one of the pathologists (KM) based on the intensity and specificity of cytoplasmic 
synaptophysin and nuclear Ki67 staining, as well as absence of background staining on the 3 
test sections (Figure 1). Thus, no further optimization was performed. Briefly, 4 micron 
paraffin-embedded sections were deparaffinized and rehydrated. Antigen retrieval was 
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performed using the DAKO PT Link instrument at 97°C for 20 minutes. Sections were 
subjected to Ki67 antibody first (20 minutes) and horseradish peroxidase (20 minutes), 
followed by synaptophysin antibody (20 minutes), G2 rabbit/mouse secondary antibody (20 
minutes), G2 alkaline phosphatase (20 minutes), G2 Permanent Red (10 minutes), and 
hematoxylin (2 minutes). Consecutive tissue sections of the same 50 GI neuroendocrine 
tumors were used to generate Ki67-only stained slides and hematoxylin and eosin-stained 
slides. The Ki67-only stained slides were prepared as per manufacturer protocol (DAKO, 
Carpinteria, CA).
Quantification of Ki67 Proliferative Index
As a first step, 3 gastrointestinal pathologists (KM, KO, DG) individually assessed the Ki67 
proliferative index of the 50 gastrointestinal neuroendocrine tumors using the 
synaptophysin-Ki67 double-stained slides. Each pathologist was instructed to select the 
tumor area of highest Ki67 positivity (i.e., hotspot) and simultaneously count the number of 
tumor cells demonstrating nuclear immunoreactivity for Ki67 and the total number of tumor 
cells (range of 500 to 2000 tumor cells). Immunopositivity for Ki67 was defined as any 
brown staining tumor nucleus, regardless of intensity of staining (as described by David 
Klimstra, personal communication, and Young et al. (10)). All counting was performed by 
visual assessment using Olympus BX41 microscopes outfitted with 10× (field number 22) 
oculars, without use of a graticule. Pathologists each chose the magnification at which 
counting was performed, and this varied from case to case. These parameters were 
deliberately chosen to simulate as much as possible typical working conditions. Pathologists 
tallied tumor cells using a free downloadable smartphone counting application of their 
choice, such as Cell Counter (https://play.google.com/store/apps/details?
id=edu.sjsu.cellcounter). Additionally, each pathologist was asked to make a note of any 
tumor for which Ki67 proliferative index appeared more challenging to assess and also 
comment on the potential source of difficulty (e.g., obscuring inflammation, entrapped non-
neoplastic glands).
To minimize the impact of recall bias, a waiting period (ranging from one week to one 
month) was instituted. The 3 pathologists then individually reviewed the set of Ki67-only 
stained slides (of the same 50 tumors), along with the corresponding hematoxylin and eosin-
stained slides. All other conditions for review of the Ki67-only stained slides were the same 
as for the double-stained slides. At the completion of the Ki67-only slide review, the 
pathologists were asked to answer a few written questions regarding ease of use of each 
Ki67 staining method (i.e., double stain, Ki67-only stain), preference of staining method, 
and the perceived benefits or shortcomings of the synaptophysin-Ki67 double stain.
As a gold standard, one pathologist (KM) independently measured the Ki67 proliferative 
index of each tumor by selecting and photographing the tumor area of highest Ki67 activity 
(on Ki67-only stained slides), printing the image on a color printer, and manually ticking off 
each immunopositive and immunonegative tumor cell with a pencil until at least 500 
neoplastic cells were counted (manual counting method). For imaging, the Infinity 2 camera 
and Infinity Analyze software (Lumenera Corporation, Ottawa, Canada) were used along 
with the HP Laserjet 6940 color printer (Hewlett Packard, Palo Alto, CA).
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Assessment of grade was determined using the World Health Organization 2010 criteria: 
grade 1 = Ki67 proliferative index ≤ 2%; grade 2 = 3-20%; grade 3 = > 20%. Numerical 
values between 2% and 3% were rounded to the nearest whole number (e.g., 2.4% was 
rounded to 2%; 2.5% was rounded to 3%), as described previously. (2, 6). This rounding 
method was also the practice of the participating pathologists at the time of the study. Of 
note, the current North American Neuroendocrine Tumor Society guidelines (14) and the 
upcoming edition of the World Health Organization Classification of Tumours of the 
Digestive System (per Dr. Ralph Hruban, personal communication) consider the Ki67 cut-
off for grade 1 gastrointestinal neuroendocrine tumors to be <3%. Utilizing this higher 
threshold increased overall grade concordance for both staining methods but did not impact 
the observed variation in Ki67 proliferative index (as described by intraclass correlation).
Statistical analysis
Intraclass correlations with 95% confidence intervals were calculated to assess inter-rater 
agreement on Ki67 proliferative index for each staining method (i.e., synaptophysin-Ki67 
double stain, Ki67-only stain) using the method of Hankinson et al., (16) with the SAS 
package from Hertzmark and Spiegelman. (17) Fisher's Z transformation was used to obtain 
P-values for testing the hypothesis that intraclass correlation = 0. A multi-rater version of the 
kappa statistic, as described by Landis and Koch (18) and implemented in the SAS macro 
magree (19) was calculated to assess inter-rater agreement for tumor grade by each staining 
method.
Friedman's rank test for blocked data was used to compare the relative scoring of Ki67 
proliferative index across pathologists to test the null hypothesis that no individual 
pathologist was systematically scoring higher or lower than the others.
Repeated measures analysis of variance was used to assess factors influencing the difference 
between proliferative index (log transformed) as rated by the 3 pathologists and the gold 
standard. Factors considered included pathologist, staining method (Ki67-only versus 
synaptophysin-Ki67 double stain), and type of specimen (biopsy versus resection). Finally, 
paired t-tests were used to compare pathologist score with gold standard score for individual 
pathologists in specific subgroups, as contrasts in order to highlight significant findings of 
the repeated measures analysis.
Results
Synaptophysin-Ki67 Double Stain
All 50 tumors were diffusely positive for synaptophysin, and all tumors demonstrated 
internal positive controls for Ki67 (e.g., endothelial cells, lymphocytes). Although the 
intensity of synaptophysin staining from case to case ranged from moderate to strong (2-3+, 
using a scale analogous to the Allred score for estrogen receptor expression in breast 
carcinoma (20)), in each case the borders of the tumor in relation to background stroma were 
sharp, allowing clear distinction of tumor from non-tumor. No significant intratumoral 
variation in synaptophysin staining was observed.
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Gold Standard
The average number of tumor nuclei counted per tumor for the gold standard assessment 
was 814 (range 500 to 1620). The mean Ki67 proliferative index of all tumors was 2.7%, 
with 62% (31 of 50 tumors) in the 1-5% range and 22% (11 of 50) in the 2-3% range. Per 
gold standard, the Ki67 proliferative index of tumors ranged from 0.4 to 16.8%. Of these, 39 
tumors were grade 1; 11 were grade 2; and none was grade 3. Overall, all 3 pathologists 
agreed with the gold standard in 32 of 50 cases when using the Ki67-only stain and in 34 of 
50 cases when using the synaptophysin-Ki67 double stain.
Interobserver Agreement
Individual pathologist scores (proliferative index, grade) for each tumor are included in 
Supplementary Data Tables 1 and 2. Ki67 index as determined by the pathologists ranged 
from 0-29.6%. Pathologist #1 counted exactly 500 tumor nuclei for each case, whereas 
pathologist #2 counted an average of 868 tumor nucleiper case (range 501-2205) and 
pathologist #3 counted an average of 1068 tumor nuclei per case (range 500-2751).
Interobserver agreement for Ki67 proliferative index and tumor grade was higher between 
pathologists when using the synaptophysin-Ki67 double stain. For Ki67 proliferative index, 
intraclass correlation between pathologists was 0.51 (95% confidence interval 0.35-0.66) 
when using the Ki67-only stain and 0.79 (95% confidence interval 0.69-0.86) when using 
the synaptophysin-Ki67 double stain (Table 1). Grade concordance among pathologists was 
present in 33 of 50 cases (kappa = 0.39, P<0.001, fair agreement) when using the Ki67-only 
stain and in 37 of 50 cases (kappa = 0.58, P<0.001, moderate agreement) when using the 
synaptophysin-Ki67 double stain (Table 2). Using a strict <3% cut-off for grade 1 
gastrointestinal neuroendocrine tumors, grade concordance among pathologists was present 
in 35 of 50 cases with the Ki67-only stain and in 38 of 50 cases with the synaptophysin-
Ki67 stain.
Analysis of individual pathologists' scores revealed that pathologist #1 tended to have the 
highest Ki67 proliferative index among the pathologists, a finding that was statistically 
significant for both staining methods (P<0.001 by Friedman test).
Subgroup analysis of pathologists' scores as compared to the gold standard revealed that 
pathologist #1 tended to overscore biopsy cases using the Ki67-only stain (P=0.02) but had 
no other systematic differences compared to the gold standard, whereas pathologists #2 and 
#3 tended to underscore cases compared to the gold standard regardless of staining method 
or specimen type (P-values ≤ 0.05) (Table 3).
Discordant Cases
Twenty cases were discordant among the pathologists using either the Ki67-only or 
synaptophysin-Ki67 staining method. Of those, 10 cases were discordant for both staining 
methods, 7 cases were discordant only with the Ki67-only method, and 3 cases were 
discordant only with the synaptophysin-Ki67 method. The most common cause of grade 
discordance for either staining method was higher grade reported by pathologist #1, 
accounting for 53% of discrepancies.
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Pathologist Feedback
Feedback from pathologists in regard to the synaptophysin-Ki67 double stain was positive 
overall, and the double stain was the stain of choice for assessment of Ki67 proliferative 
index. Pathologists cited improved confidence when counting tumor nuclei in areas 
containing a significant number of obscuring non-neoplastic cells as the primary reason for 
their preference of the synaptophysin-Ki67 double stain (Figure 2).
Pathologists were also asked to note those cases with which they experienced particular 
difficulty evaluating the Ki67 proliferative index. In total, 17 different cases were identified 
by the pathologists as being challenging to assess due to obscuring non-neoplastic cells 
(Supplementary Table 3). Of these, 6 cases were discrepant using the Ki67-only slides, 
whereas only 2 cases (a subset of the 6) were discrepant using the synaptophysin-Ki67 
stained slides. In 4 of the 17 cases, 2 or more comments were made by pathologists 
regarding challenges in interpretation related to obscuring non-neoplastic cells. Of these, 3 
of 4 tumors showed grade discordance with the Ki67-only stain. In contrast, all 4 tumors 
were grade concordant with the synaptophysin-Ki67 double stain (Figure 3).
Discussion
It is now well established that performing a Ki67 count is necessary for all gastrointestinal 
neuroendocrine tumors, as endorsed by the World Health Organization, European 
Neuroendocrine Tumor Society, American Joint Committee on Cancer, College of American 
Pathologists, and North American Neuroendocrine Tumor Society. This mandate is based on 
a large body of evidence demonstrating that the Ki67 proliferative index holds prognostic 
significance. However, implicit within this mandate is a requirement that the count be 
accurate and reproducible. Precision is a key issue in the usefulness of numerical cut-offs for 
grading, and thus identifying sources of interobserver variation and developing strategies to 
overcome them is essential. Also critical is the need to balance improvements in precision 
with consideration of laboratories' financial resources (particularly across an international 
community) and their impact on pathologists' workload and turnaround time.
Obscuring non-tumor Ki67-positive nuclei are a well-known source of error in deriving the 
Ki67 proliferative index of gastrointestinal neuroendocrine tumors. (5, 7, 21) Unlike 
automated image analysis and manual image analysis which focus on simplifying the 
arduous task of counting 500-2000 tumor cells, the synaptophysin-Ki67 double stain is the 
first technique specifically directed at overcoming human error related to distinguishing 
(gastrointestinal neuroendocrine) tumor from non-tumor. Importantly, errors related to mis-
assignment of Ki67-positive nuclei to tumor are mathematically far more deleterious to 
precision than are accidentally including a few more (or missing a few) Ki67-negative tumor 
nuclei. While there are some automated image analysis programs that will consider nuclear 
size and shape in order to avoid counting lymphocytes and/or stromal cells, there is some 
disagreement regarding how successful these programs are. (5, 21) In addition, such 
programs require substantial capital investment and considerable technical expertise. More 
recently, free online image analysis tools utilizing photo-captured tumors have become 
available. (22, 23) These software programs decrease capital costs but suffer from the same 
limitations as other automated tools in regard to distinguishing tumor from non-tumor.
Matsukuma et al. Page 7
Mod Pathol. Author manuscript; available in PMC 2017 July 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The synaptophysin-Ki67 double stain was developed with minimal technical expertise 
(above and beyond what is necessary in a lab performing routine automated 
immunohistochemistry) and required a minimal number of validation steps. Furthermore, 
per manufacturer, the antibody vials need not be dedicated to the double stain technique. 
That is, the same vial of Ki67 antibody routinely used as a single immunostain (for example, 
for the evaluation of breast and hematolymphoid malignancies) can be used for the double 
stain, albeit not simultaneously. Similarly, the same vial of synaptophysin antibody used as a 
general marker of neuroendocrine differentiation can be used for both single and double 
chromogen applications. Thus, the main added cost is the double stain kit itself. This price 
varies according to institutional contract, and our local representative quoted the following 
prices: US$2847.95 for the Envision Flex Mini Kit, High pH, 125-190 tests (DAKO 
K802321) and US$1184.50 for Envision G2 System/AP, Rabbit/Mouse Permanent Red, 50 
tests (DAKO K535511). Certainly, this is an upfront cost that would need to be considered 
in the utilization of this methodology.
On the surface, the interobserver agreement (as demonstrated by intraclass correlations and 
kappa statistics) might appear relatively low in the current study as compared to other 
interobserver studies on Ki67 scoring. (7, 10, 24) However, in these other studies, hotspot 
selection was taken out of the equation by having pathologists review pre-determined fields 
or tissue microarray samples, (4, 7, 10, 24, 25) both of which have essentially a single field 
for counting Ki67-positive nuclei. This format, while easing the task of the study's 
pathologists, does not reflect typical working conditions, and thus limits its applicability to 
general practice. Emphasizing the importance of this, Adsay noted, “In our experience, 
almost half of the cases are placed in a different World Health Organization grade on the 
basis of the area chosen for counting.” (22) In our study, interobserver agreement for Ki67-
only stained slides was similar to that seen by Reid et al. (21) using their “manual eye count” 
– a method equivalent to that used in the current study. It is also worthwhile noting that a 
subset of studies focuses solely on pancreatic neuroendocrine tumors (8, 21, 26) – which are 
morphologically more homogeneous with few peri-tumoral stromal lymphocytes or 
entrapped non-neoplastic glands. Thus, these studies may not capture the intricacies related 
to assessing Ki67 proliferative index of gastrointestinal neuroendocrine tumors in general.
At the same time, our approach which left many more variables in the test system was also a 
limitation of the study. A more focus approach utilizing images of the same area of tumor on 
both the Ki67-only and synaptophysin-Ki67 stained slides would have assessed more 
specifically the value of the double stain method in distinguishing tumor from non-tumor. 
Additionally, by allowing pathologists to count within a range of 500-2000 tumor cells, we 
found there was a wide variation in the number of tumor cells counted. In particular, 
pathologist #1 counted 300-500 fewer tumor cells on average than the other 2 pathologists. 
This correlated with generally higher grade designations, a finding previously observed by 
others. (4) Notably, higher grade designations by pathologist #1 were the most common 
cause of grade discordance among the pathologists, accounting for a majority of the grade 
discrepancies for both staining methods. Thus, counting method alone may have a 
significant impact on grade.
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While we were not expecting to find any significant differences in pathologists' scores in 
relation to the gold standard, the fact that pathologist #1 tended to overscore biopsies (but 
not resections) was intriguing. It seems plausible that because the choice of hotspot is more 
limited in biopsies, more frequent counting in areas containing obscuring non-tumor Ki67-
positive cells may be necessary, a situation in which there is increased risk of over-counting. 
In addition, both pathologists #2 and #3 underscored all tumors regardless of staining 
method compared to the gold standard; one possibility is that eye counting over-counts the 
number of Ki67-negative tumor nuclei compared to the manual counting method (i.e., 
ticking off tumor nuclei on a printed image). Of note, we chose the eye counting method for 
this study because it reflects our current practice; however, the findings suggest a re-
evaluation of this protocol is warranted.
In conclusion, this study provides preliminary evidence that the synaptophysin-Ki67 double 
stain improves interobserver agreement in the grading of well-differentiated gastrointestinal 
neuroendocrine tumors. Although improved grade concordance was restricted to a small 
number of cases, the overall increase in agreement on Ki67 proliferative index (as described 
by intraclass correlation) is significant in that it is a measure entirely independent of grade 
thresholds. Furthermore, that grade concordance specifically improved in the subset of cases 
deemed challenging by pathologists emphasizes the value of the synaptophysin-Ki67 stain 
for its intended purpose and suggests that its greatest utility is in this pathologist-defined set 
of cases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Validation of the synaptophysin-Ki67 double stain, validation case #3. (a) Hematoxylin and 
eosin stain. (b) Synaptophysin-Ki67 double stain. (c) Synaptophysin-Ki67 double stain. All 
images digitally scanned at 20× magnification.
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Figure 2. 
The synaptophysin-Ki67 double stain enhances distinction of tumor from non-tumor, 
particularly in the presence of proliferating intratumoral vessels (a, b, test case #17), 
entrapped non-neoplastic glands (c,d, test case #22), and crush artifact (e,f, test case #29). 
Left panel, Ki67-only stain; right panel, synaptophysin-Ki67 double stain. All images 
digitally scanned at 20× magnification.
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Figure 3. 
Three cases considered challenging in regard to assessment of Ki67 proliferative index. (a,b) 
Test case #2: This case was grade discordant when the pathologists reviewed the Ki67-only 
stained slide but grade concordant on the synaptophysin-Ki67 slide. (c,d) Test case #12: This 
case was grade discordant on the Ki67-only stained slide and grade concordant on the 
synaptophysin-Ki67 slide. (e,f) Test case #41. This case was considered challenging but was 
nonetheless grade concordant on both the Ki67 and synaptophysin-Ki67 stained sections. 
Left panel, Ki67-only stain; right panel, synaptophysin-Ki67 double stain. All images 
digitally scanned at 20× magnification.
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Table 1
Intraclass correlations for Ki67 proliferative index of 50 well-differentiated 
gastrointestinal neuroendocrine tumors using the Ki67-only and Synaptophysin-Ki67 
slide sets (all 3 pathologists)
Staining Method Intraclass correlation (95% confidence interval) P-value†
Ki67-only 0.51 (0.35-0.66) <0.001
Synatophysin-Ki67 0.79 (0.69-0.86) <0.001
†2-sided vs. H0:r=0
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Table 2
Multi-rater Kappa values for grade of 50 well-differentiated gastrointestinal 
neuroendocrine tumors using the Ki67-only and Synaptophysin-Ki67 slide sets (all 3 
pathologists)
Staining Method κ-value P-value
Ki67-only 0.39 <0.001
Synaptophysin-Ki67 0.58 <0.001
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Table 3
Analysis of Ki67 proliferative index by pathologist, staining method, and specimen type - 
compared to gold standard (biopsy and/or resection, as relevant)
Variable Estimate† Standard Error P-value
Pathologist #1
 Ki67-only stain
  Biopsies and resections 0.224 0.099 0.030
  Biopsies only 0.317 0.127 0.020
  Resections only 0.096 0.157 0.550
 Synaptophysin-Ki67 stain
  Biopsies and resections -0.018 0.123 0.880
  Biopsies only 0.121 0.127 0.350
  Resections only -0.230 0.239 0.350
Pathologist #2
 Ki67-only stain
  Biopsies and resections -0.408 0.097 0.0001
  Biopsies only -0.242 0.101 0.020
  Resections only -0.637 0.174 0.002
 Synaptophysin-Ki67 stain
  Biopsies and resections -0.382 0.099 0.0003
  Biopsies only -0.428 0.130 0.003
  Resections only -0.319 0.156 0.050
Pathologist #3
 Ki67-only stain
  Biopsies and resections -0.562 0.078 <0.0001
  Biopsies only -0.626 0.100 <0.0001
  Resections only -0.473 0.123 0.001
 Synaptophysin-Ki67 stain
  Biopsies and resections -0.378 0.087 <0.0001
  Biopsies only -0.342 0.109 0.004
  Resections only -0.434 0.156 0.008
†
Estimate is the mean of the difference of proliferative index on a log scale between pathologists and gold standard (pathologist-gold standard)
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